Advanced search×
×

Expert Opinion on Investigational Drugs

Print ISSN
1354-3784
Electronic ISSN
1744-7658
Impact factor
4.337
Publisher
Proquest
URL
http://informahealthcare.com/journal/eid
Usage rank
1216
Article count
2343
Free count
1
Free percentage
0.000426803
PDFs via platforms
CSA, Proquest, Ingenta, Informaworld, Rcgp, and Informahealthcare

  1. Recent advances in the development of telomerase inhibitors for the treatment of cancer.

    Expert Opinion on Investigational Drugs 8(12):1981 (1999) PMID 11139836

    We review recent advances in the development of telomerase inhibitors for the treatment of cancer. To date, these have included antisense strategies, reverse transcriptase inhibitors and compounds capable of interacting with high-order telomeric DNA tetraplex ('G-quadruplex') structures to prevent e...
  2. DNA vaccines for cancer therapy.

    Expert Opinion on Investigational Drugs 8(12):2017 (1999) PMID 11139838

    Vaccination with a tumour antigen-expressing plasmid DNA (pDNA) is a novel approach to human cancer immunotherapy. Initial results in preclinical rodent tumour models are promising, revealing that pDNA cancer vaccines can elicit both humoral, as well as cell-mediated immunity and, in...
  3. Endothelin receptor antagonists: novel agents for the treatment of hypertension?

    Expert Opinion on Investigational Drugs 8(11):1807 (1999) PMID 11139826

    We now possess direct evidence that such drugs are effective as antihypertensives in some experimental models of hypertension. Furthermore, the ability of ET-receptor antagonists to prevent hypertension-induced end-organ damage is also well documented. Their capacity to reverse already established t...
  4. Rosiglitazone: a new therapy for Type 2 diabetes.

    Expert Opinion on Investigational Drugs 8(10):1709 (1999) PMID 11139821

    Rosiglitazone (Avandiatrade mark) is a new generation thiazolidinedione used in the treatment of Type 2 diabetes. As with other thiazolidinediones, it binds to the gamma-isoform of the peroxisome proliferator-activated receptor (PPAR), a nuclear hormone receptor. Subsequent to PPAR-g...
  5. Erratum.
    Author(s) unavailable

    Expert Opinion on Investigational Drugs 18(6):873 (2009) PMID 19466876

  6. Therapeutic advances in idiopathic Parkinsonism.

    Expert Opinion on Investigational Drugs 8(10):1565 (1999) PMID 11139811

    Parkinson's disease (PD) is the only neurodegenerative disorder in which pharmacological intervention has resulted in a marked decrease in morbidity and a significant delay in mortality. The discovery of striatal dopamine deficiency as the neurochemical basis of PD in 1960 was a pivo...
  7. An array of immunotherapeutic strategies for B-cell lymphomas.

    Expert Opinion on Investigational Drugs 8(12):2059 (1999) PMID 11139840

    I and II trials. Even antisense approaches have reappeared in the treatment of NHL. However, it is not only passive immunotherapy that has evolved. There are several new strategies for vaccination in NHL, whilst older approaches are under revision. Vaccine strategies targeting the tumour cell specif...
  8. New anti-epileptic drugs.

    Expert Opinion on Investigational Drugs 8(10):1497 (1999) PMID 11139806

    We consider the possible physiological targets for anti-epileptic drugs, the animal models of epilepsy, problems with clinical trials and ten promising anti-epileptic drugs in development (AWD 131-138, DP16 (DP-VPA), ganaxolone, levetiracetam, losigamone, pregabalin, remacemide, retigabine, rufinami...
  9. Genetic therapies and xenotransplantation.

    Expert Opinion on Investigational Drugs 8(10):1653 (1999) PMID 11139817

    There is an acute shortage of human organs available for transplantation. Transplanting animal organs or tissues is a potential solution and could also provide a novel means of gene delivery. Xenotransplantation faces many challenges, including the immune response of the recipient ag...
  10. Related articles.
    Author(s) unavailable

    Expert Opinion on Investigational Drugs 21(10):1 (2012) PMID 22978319